DK2349295T3 - Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer - Google Patents

Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer Download PDF

Info

Publication number
DK2349295T3
DK2349295T3 DK09826377.5T DK09826377T DK2349295T3 DK 2349295 T3 DK2349295 T3 DK 2349295T3 DK 09826377 T DK09826377 T DK 09826377T DK 2349295 T3 DK2349295 T3 DK 2349295T3
Authority
DK
Denmark
Prior art keywords
strains
ncimb
pharmaceutical composition
strain
staphylococcus
Prior art date
Application number
DK09826377.5T
Other languages
English (en)
Inventor
Kristian Roos
Hã¥Kansson Eva Grahn
Original Assignee
Winclove Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winclove Holding B V filed Critical Winclove Holding B V
Application granted granted Critical
Publication of DK2349295T3 publication Critical patent/DK2349295T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (16)

1. Farmaceutisk præparat til profylakse mod og behandling af Staphylococcus-induce-rede infektioner eller tilstande i mennesker og dyr, hvor det omfatter en kombination af a) én eller flere levedygtige α-Streptococcus-stammer, som er valgt fra gruppen bestående af Streptococcus sanguis Il-stammerne med deponeringsnumrene NCIMB 40104, NCIMB 40105, NCIMB 40106 og NCIMB 40873, Streptococcus mitis-stammerne med deponeringsnumrene NCIMB 40107 og NCIMB 40874, Streptococcus oralis-stammerne med deponeringsnumrene NCIMB 40875 og NCIMB 40876, Streptococcus lactis-stammen L1A med deponeringsnummeret NCIMB 40157; og b) én eller flere levedygtige Lactobacillus-stammer, som er valgt fra gruppen bestående af Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564, Lactobacillus plantarum-stammen LB3 med deponeringsnummeret DSM 17852, Lactobacillus plantarum-stammen LB7 med deponeringsnummeret DSM 17853, Lactobacillus plantarum-stammen LB931 med deponeringsnummeret DSM 11918 og Lactobacillus fermentum-stammen LB Ess-1 med deponeringsnummeret DSM 17851; i mindst ét farmaceutisk acceptabelt medium, i hvilket stammerne bevarer deres levedygtighed.
2. Farmaceutisk præparat ifølge krav 1, hvor det omfatter en kombination afa) Streptococcus sanguis-stammerne med deponeringsnumrene NCIMB 40104 og NCIMB 40106 og Streptococcus oralis-stammen med deponeringsnummeret NCIMB 40876, og b) Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564.
3. Farmaceutisk præparat ifølge krav 2, hvor det omfatter en kombination af Streptococcus sanguis Il-stammen med deponeringsnummeret NCIMB 40104 og Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564.
4. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor den ene eller de flere Streptococcus-stammer er til stede i en samlet mængde på 104-1011, fortrinsvis 105-1010, mest fortrinsvis 106-109, kolonidannende enheder pr. ml af det brugsklare præparat, og hvor den ene eller de flere Lactobacillus-stammer er til stede i en mængde på 104-1011, fortrinsvis 105-1010, mest fortrinsvis 106-109, kolonidannende enheder pr. ml af det brugsklare præparat.
5. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det er en oral, oromucosal, gingival, nasal, dental, kutan/hud, vaginal, rektal eller øreformule-ring.
6. Farmaceutisk præparat ifølge krav 5, hvor det hårform af et pulver, et granulat, en ’’cachet”, en kapsel, en tablet, en pasta, en creme, en gel, en sårsalve, en salve, en skum, en pasta, en lotion, en creme, en oliesuspension, en spray, en suspension, en opløsning, en emulsion, et plaster, en stav, en spray, fortrinsvis en nasal spray, eller en buccal spray, et mundskyllemiddel eller en drik eller opløsning.
7. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det farmaceutisk acceptable medium er et syrnet eller fermenteret mælkeprodukt, fortrinsvis syrnet mælk, yoghurt og mælk eller frugtjuice, iscreme, suppe og frugtdrikke.
8. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det farmaceutisk acceptable medium er et dyrefoder, fortrinsvis valle, tørfoder eller en koncentreret suspension, når præparatet ifølge opfindelsen administreres til dyr.
9. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor stammerne deri er lyofiliserede.
10. Farmaceutisk præparat ifølge krav 9, hvor det er til stede i en NaCI-opløsning, en glukoseopløsning eller skummetmælk.
11. Kit til profylakse mod og behandling af Staphylococcus-inducerede infektioner eller tilstande, hvor det omfatter to eller flere separate formuleringer, som er beregnet til at blive administreret samtidigt eller i rækkefølge inden for en forudbestemt tidsperiode, fortrinsvis inden for 24 timer, til et menneske eller et dyr, som har behov derfor, hvor kittet omfatter en kombination af stammer ifølge krav 1a) og stammer ifølge krav 1b), hvor hver formulering i kittet omfatter mindst én stamme ifølge krav 1a) og/eller mindst én stamme ifølge krav 1 b).
12. Farmaceutisk præparat ifølge et hvilket som helst af kravene 1-10 eller kit ifølge krav 11 til anvendelse i en fremgangsmåde til profylakse mod og/eller behandling af en Staphylococcus-induceret infektion eller tilstand.
13. Farmaceutisk præparat eller kit til anvendelse ifølge krav 12, hvor den Staphylo-coccus-inducerede infektion eller tilstand er induceret af Staphylococcus aureus-, Staphylococcus epidermidis- og/eller Staphylococcus saprophyticus-stammer, især multiresistente Staphylococcus aureus-(MRSA)-stammer.
14. Farmaceutisk præparat eller kit til anvendelse ifølge krav 13, hvor den Staphylo-coccus-inducerede infektion eller tilstand er til stede i mundhulen, i øret, i den nasale og/eller faryngale region, i mave/tarmkanalen, på huden eller andre steder eller organer i kroppen.
15. Farmaceutisk præparat eller kit til anvendelse ifølge krav 12, hvor den Staphylo-coccus-inducerede infektion eller tilstand er mindre hudinfektioner, fortrinsvis bumser, impetigo, bylder, cellulitis folliculitis, furunkler, karbunkler, skoldet hudsyndrom og abscesser, samt livstruende sygdomme, fortrinsvis lungebetændelse, meningitis, osteomyelitis, endocarditis, toksisk shocksyndrom (TSS) og septikæmi.
16. Anvendelse af et farmaceutisk præparat ifølge et hvilket som helst af kravene 1-10 eller kit ifølge krav 11 til fremstilling af et lægemiddel til profylakse mod og/eller behandling af Staphylococcus-inducerede infektioner eller tilstande i mennesker og dyr.
DK09826377.5T 2008-11-17 2009-11-17 Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer DK2349295T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11528308P 2008-11-17 2008-11-17
SE0850079 2008-11-17
PCT/SE2009/051300 WO2010056198A1 (en) 2008-11-17 2009-11-17 Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains

Publications (1)

Publication Number Publication Date
DK2349295T3 true DK2349295T3 (da) 2017-01-23

Family

ID=42170160

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09826377.5T DK2349295T3 (da) 2008-11-17 2009-11-17 Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer

Country Status (10)

Country Link
US (2) US20110256179A1 (da)
EP (1) EP2349295B8 (da)
CN (1) CN102215849A (da)
AU (1) AU2009314666B2 (da)
CA (1) CA2742727A1 (da)
DK (1) DK2349295T3 (da)
IL (1) IL212698A (da)
PL (1) PL2349295T3 (da)
RU (1) RU2011124506A (da)
WO (1) WO2010056198A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US8927242B2 (en) * 2012-05-10 2015-01-06 Nubiome, Inc. Treatment and prophylaxis for obsessive compulsive disorder
FR2999601B1 (fr) * 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
WO2015140299A1 (en) * 2014-03-20 2015-09-24 Universiteit Antwerpen Oronasopharyngeal probiotics
EP3015109B1 (en) * 2014-10-28 2019-09-18 D.M.G. Italia Srl Biological barrier with simethicone for the use in the treatment of naso-pharyngo-tubal infections
WO2016172686A1 (en) * 2015-04-24 2016-10-27 The Translational Genomics Research Institute Compositions and methods for augmenting the nasal microbiome
WO2020001747A1 (en) 2018-06-26 2020-01-02 Symrise Ag Lactobacillus plantarum for skin care
CN113194971A (zh) 2018-09-10 2021-07-30 拉克托拜欧有限公司 用于减少病原微生物转移的方法
KR102167387B1 (ko) * 2020-05-14 2020-10-19 코스맥스 주식회사 피부 장벽 강화, 피부 보습 또는 항노화를 위한 조성물
CN113462616A (zh) * 2021-08-19 2021-10-01 上海昊岳食品科技有限公司 一株人源鼠李糖乳杆菌glr8及其制备方法
KR20260084912A (ko) * 2024-11-29 2026-06-08 주식회사 종근당바이오 건강한 성인의 피부에서 분리한 균주를 포함하는 여드름의 예방 또는 치료용 조성물
CN119464165B (zh) * 2025-01-16 2026-02-24 中日友好医院(中日友好临床医学研究所) 口腔链球菌zrsor-5及其相关产品、方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE461310B (sv) 1988-07-12 1990-01-29 Ellemtel Utvecklings Ab Saett och anordning foer att i en digital tidsvaeljare genomkoppla en bredbandsfoerbindelse
SE463349B (sv) 1989-02-15 1990-11-12 Grahn Eva E Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit
SE465206B (sv) * 1989-12-22 1991-08-12 Eva Grahn Farmaceutisk beredning foer bekaempning av patogena tarmbakterier
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
RO112995B1 (ro) * 1997-08-05 1998-03-30 Rodica Teodorescu Produs medicamentos pentru terapia colonului
SE519648C2 (sv) * 1998-03-06 2003-03-25 Essum Ab Ny stam av Lactobacillus plantarum
SE511648C2 (sv) 1998-04-17 1999-11-01 Bacterum Ab Streptokockpreparat för behandling av öroninflammation
CA2354054C (en) * 1998-12-11 2011-04-12 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
TW588109B (en) * 2000-07-29 2004-05-21 Tcell Biotechnology Food Co Lt Lactobacillus rhamnosus strain and uses thereof
US20030175305A1 (en) * 2002-01-08 2003-09-18 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
US20060258596A1 (en) * 2003-02-14 2006-11-16 Walsh Timothy R Antimicrobial agents
EP1481681A1 (en) * 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2007108763A1 (en) * 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease

Also Published As

Publication number Publication date
EP2349295A4 (en) 2012-12-12
RU2011124506A (ru) 2012-12-27
EP2349295B1 (en) 2016-10-26
US20110256179A1 (en) 2011-10-20
CN102215849A (zh) 2011-10-12
PL2349295T3 (pl) 2017-06-30
WO2010056198A1 (en) 2010-05-20
CA2742727A1 (en) 2010-05-20
AU2009314666A1 (en) 2010-05-20
AU2009314666B2 (en) 2015-01-29
US10596244B2 (en) 2020-03-24
EP2349295B8 (en) 2016-12-14
IL212698A (en) 2013-12-31
IL212698A0 (en) 2011-07-31
US20160089428A1 (en) 2016-03-31
EP2349295A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
US10596244B2 (en) Pharmaceutical preparation comprising a combination of Streptococcus strains and lactobacillus strains
Fuller Probiotics 2: applications and practical aspects
AU2019379234B2 (en) Strains, composition and method of use
CN1639318B (zh) 抗微生物组合物
US20020022019A1 (en) Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments
EP1162987B1 (en) Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome
JPH10287585A (ja) 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
ES2331650T3 (es) Utilizacion de bacterias probioticas en el tratamiento de una infeccion.
JP2013522315A (ja) 胃腸状態の予防及び処置にバチルス・ズブチリス菌株を使用する方法
ES2373411T3 (es) Inhibición del crecimiento y eliminación del staphylococcus aureus resistente a la meticilina por bacterias ácido lácticas.
JP2001002578A (ja) Helicobacterpylori除菌性医薬品
WO2017105267A1 (en) New probiotic starter culture for human and animal use
KR100409940B1 (ko) 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품
Cresci Clinical research: The use of probiotics with the treatment of diarrhea
Cazzato et al. Role of probiotics in Helicobacter pylori infections
KR100437487B1 (ko) 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품
Kroeker et al. Treatment of Ulcerative Colitis
Sharma et al. AN OVERVIEW: PROBIOTIC MICROBES
Kaul et al. Probiotics: stepping stone towards a healthy life